Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.82M Hold
23,402
0.23% 79
2025
Q4
$2.46M Sell
23,402
-515
-2% -$48.3K 0.2% 84
2025
Q3
$2.01M Sell
23,917
-2,173
-8% -$179K 0.17% 90
2025
Q2
$2.07M Sell
26,090
-648
-2% -$51.5K 0.19% 89
2025
Q1
$2.4M Sell
26,738
-898
-3% -$83.8K 0.23% 84
2024
Q4
$2.75M Sell
27,636
-2,449
-8% -$252K 0.26% 75
2024
Q3
$3.42M Sell
30,085
-93
-0.3% -$11K 0.33% 69
2024
Q2
$3.74M Sell
30,178
-410
-1% -$52.8K 0.39% 61
2024
Q1
$4.04M Buy
30,588
+7
+0% +$863 0.42% 62
2023
Q4
$3.33M Buy
30,581
+8
+0% +$830 0.39% 62
2023
Q3
$3.15M Buy
30,573
+1,577
+5% +$170K 0.4% 60
2023
Q2
$3.35M Sell
28,996
-328
-1% -$37.2K 0.41% 62
2023
Q1
$3.12M Buy
29,324
+8
+0% +$864 0.4% 63
2022
Q4
$3.25M Buy
29,316
+9
+0% +$920 0.45% 58
2022
Q3
$2.52M Sell
29,307
-2
-0% -$179 0.36% 64
2022
Q2
$2.67M Sell
29,309
-11
-0% -$975 0.36% 67
2022
Q1
$2.41M Buy
29,320
+3,872
+15% +$305K 0.27% 81
2021
Q4
$1.95M Buy
25,448
+2,009
+9% +$160K 0.22% 90
2021
Q3
$1.76M Buy
23,439
+17,931
+326% +$1.36M 0.22% 90
2021
Q2
$428K Buy
5,508
+1,679
+44% +$125K 0.05% 120
2021
Q1
$282K Buy
3,829
+9
+0.2% +$664 0.04% 125
2020
Q4
$298K Sell
3,820
-123
-3% -$9.41K 0.04% 125
2020
Q3
$312K Buy
3,943
+324
+9% +$25.4K 0.05% 114
2020
Q2
$267K Sell
3,619
-198
-5% -$14.9K 0.05% 116
2020
Q1
$280K Buy
3,817
+24
+0.6% +$1.89K 0.06% 108
2019
Q4
$329K Buy
3,793
+26
+0.7% +$2.14K 0.05% 112
2019
Q3
$303K Buy
3,767
+8
+0.2% +$641 0.05% 117
2019
Q2
$301K Buy
3,759
+7
+0.2% +$536 0.05% 117
2019
Q1
$298K Buy
3,752
+883
+31% +$66K 0.06% 116
2018
Q4
$209K Buy
+2,869
New +$203K 0.04% 126
2017
Q4
Sell
-3,802
Closed -$232K 129
2017
Q3
$232K Buy
3,802
+399
+12% +$24.2K 0.05% 112
2017
Q2
$208K Buy
+3,403
New +$207K 0.05% 114

Other funds holding MRK

Callahan Advisors's MRK Position: Q1 2026 in Review

Callahan Advisors held its Merck (MRK) position steady in Q1 2026 at 23,402 shares worth $2.82M. The position accounts for 0.23% of the portfolio, ranked #79.

Callahan Advisors first reported a position in MRK in Q2 2017 and has held it in 32 quarters since. The position peaked at $4.04M in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Callahan Advisors held 23,402 shares of Merck worth $2.82M as of Q1 2026.
  • Callahan Advisors left its Merck share count unchanged in Q1 2026.
  • Merck made up 0.23% of Callahan Advisors's portfolio in Q1 2026, its #79 holding.
  • Callahan Advisors first reported a position in Merck in Q2 2017 and has held it in 32 quarters since.
  • Callahan Advisors's Merck position peaked at $4.04M in Q1 2024.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.